Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-03-04
2001-05-01
Fredman, Jeffrey (Department: 1655)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120
Reexamination Certificate
active
06225451
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates generally to the field of human genetics. The present invention specifically relates to a human coronary heart disease susceptibility gene (CHD1), some alleles of which are related to susceptibility to coronary heart disease. More specifically, the present invention relates to germline mutations in the CHD1 gene and their use in the diagnosis of predisposition to coronary heart disease and to metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, obesity, diabetes and dyslipidemic hypertension.
The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the CHD1 gene (including gene therapy, protein replacement therapy, and administration of protein mimetics and inhibitors).
Also within the scope of this invention is the screening of drugs for coronary heart disease or metabolic disorder therapy.
The invention further relates to the screening in patients of the CHD1 gene for mutations, such screening is useful for diagnosing the predisposition to coronary heart disease and to metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, obesity, diabetes and dyslipidemic hypertension.
Also within the scope of this invention are binding assays utilizing the proteins of the invention.
Also within the scope of this invention are antibodies directed against protein products encoded by the CHD1 gene, hybridomas secreting the antibodies, and diagnostic kits comprising those antibodies.
Methods for using the CHD1 polypeptides, CHD1 DNA sequences, polynucleotide primers, and antisense sequences directed at the CHD1 locus and the aforementioned antibodies are also within the scope of this invention.
BACKGROUND OF THE INVENTION
Coronary heart disease (CHD) or coronary artery disease (CAD) is one of the major causes of death in the United States, accounting for about a third of all mortality. Studies of early CHD sib pairs have identified several risk factors that contribute to CHD (Goldstein, et al., 1973; Hazzard, et al., 1973; and Williams, et al., 1990)*. These dyslipidemic phenotypes and their frequency in cases of early familial coronary disease include: familial hypercholesterolemia (high LDL cholesterol), 3-4%; Type III hyperlipidemia (Apo E2/E2 genotype), 0.5 to 3%; low HDL-cholesterol (HDL-C, also called hypobetalipoproteinemia), 20 to 30%; familial combined hyperlipidemia (FCH—high LDL-cholesterol and/or high triglycerides and/or high VLDL-cholesterol), 20-36%; familial hypertriglyceridemia, about 20%; high Lp(a), 16 to 19%; high homocysteine, 15 to 30%; or no known concordant risk factors 10 to 20% (Williams, et al., 1990). Thus, a familial history of CHD is a risk factor independent of known physiological abnormalities (Hopkins, et al., 1988, Jorde, et al., 1990).
* A list of References is appended herein, providing full citations of the references.
Several metabolic disorders are associated with increased risk of CHD. These include familial dyslipidemic hypertension (Williams, et al., 1990; Williams, et al., 1993), insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young (MODY), insulin resistant syndrome X (Castro-Cabezas, et al., 1993; Kawamoto, et al., 1996; Landsberg, 1996; Hjermann, 1992; Vague and Raccah, 1992), hyperthyroidism and hypothyroidism (de Bruin, et al., 1993; Blangero, et al., 1996) and obesity (Iverius, et al., 1985). Recent analyses indicate the possibility that a single defect, perhaps the amount of visceral body fat, may underlie many of these syndromes (Hopkins, et al., 1996).
The underlying genetic causes of the majority of CHD deaths are not known. In addition, the genetics of many of the underlying metabolic disorders are not completely understood. These metabolic disorders are generally described as “genetically complex”. In addition, the disorders themselves are fairly common in the population, so one possibility is that common alleles at some loci predispose to the disorders, making these alleles difficult to distinguish from common (non-causal) polymorphisms. In addition, the disease causing alleles may have low penetrance. The diseases also develop over a large number of years, thus creating the situation that a relatively minor alteration in the function of the predisposing gene(s) can, over a lifetime, have severe metabolic and phenotypic consequences. Thus, the disease-causing alleles may not be obviously deleterious to gene function. Finally, many metabolic diseases show significant co-morbidity, raising the possibility that multiple phenotypes might be associated with a single gene. The penetrances of the individual disorders may be influenced by different alleles of the gene or by environmental or genetic background effects, and may differ between or within families segregating mutations in the predisposing gene(s).
Some risk factors appear relatively simple genetically. For instance, lipoprotein (a) (Lp(a)) levels are strongly correlated with CHD. Greater than 95% of the variation in Lp(a) protein levels is associated with the gene itself, and is mostly related to the number of Kringle repeats in the gene (DeMeester, et al., 1995). The role of the LDL receptor in lipid metabolism and CHD is another example. The familial hypercholesterolemia (FH) syndrome is a rare syndrome (affecting about 1 in 500 individuals) characterized by very high low-density lipoprotein (LDL)-cholesterol, and very early CHD, usually manifest in the 20s or 30s. Early family studies identified and clinically defined obligate FH heterozygotes, and allowed for the positional cloning of the gene responsible for FH, the LDL receptor. About half of FH index cases can be found to carry mutations in the LDL receptor gene, and at least 373 distinct mutations have been identified in the LDL receptor to date (a database of identified mutations can be found at www.ucl.ac.uk/fh/). These mutations cover the full extent of possible deleterious mutations. Included are point mutations that alter the function of the receptor or the expression of the gene, small insertions and deletions causing frameshifts in the coding region and large genomic rearrangements that cause substantial alterations in the gene's structure, resulting in altered gene expression.
On the other hand, some dyslipidemias appear to be genetically quite complex. For instance, about half of the variation in high-density lipoprotein-C (HDL-C) levels appear to be genetically determined (Friedlander, et al., 1986a; Friedlander, et al., 1986b; Moll, et al., 1989; Perusse, et al., 1989; Prenger, et al., 1992; Cohen, et al., 1994). Defects in several genes are known to cause low HDL-C including apolipoprotein AI (ApoAI) deficiency, apolipoprotein B (ApoB) polymorphisms (Peacock et al., 1992), lipoprotein lipase (LPL) deficiency and lecithin:cholesterol acetyltransferase (LCAT) deficiency (recently reviewed in Funke, 1997). However, in aggregate these known genetic defects account for only a very small proportion of individuals with low HDL. Some studies have shown association of HDL-C levels with the hepatic triglyceride lipase and ApoAI, CIII AIV loci (e.g. Cohen, et al., 1994), indicating that a significant portion of the genetic effects may come from these loci, though other studies have failed to find such an association (Bu, et al., 1994; Maheny, et al., 1995; Marcil, et al., 1996). Additionally, the ApoAI, CIII and AIV loci have been associated with familial combined hyperlipidimia (FCH) in some studies (Wojciechowski, et al., 1991; Tybjaerg-Hansen, et al., 1993, Dallinga-Thie, et al., 1997), but not others (Xu, et al., 1994).
Another complexity of the dyslipidemias is illustrated by the LPL gene. Heterozygotes for some LPL mutations show higher triglycerides and lower HDL-C, and no elevation in LDL-C, and high systolic blood pressure when compared
Ballinger Dennis G.
Ding Wei
Hess Mark A.
Wagner Susanne
Chakrabarti Arun
Fish & Neave
Fredman Jeffrey
Haley, Jr., Esq. James F.
Liang Stanley D.
LandOfFree
Chromosome 11-linked coronary heart disease susceptibility... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromosome 11-linked coronary heart disease susceptibility..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromosome 11-linked coronary heart disease susceptibility... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2451116